As challenges in the U.S.-China bilateral relationship continue to affect the business environment under the new Biden administration, it is important to understand the outlook for collaboration with the fast-growing biotech sector in China and what it means for advancements in the global life sciences industry in a post-COVID world. With China entering its new five-year state-planning period (2021-2025), China’s biopharma sector is positioned for significant growth as a strategic emerging industry. Meaningful cross-border collaborations—including in early-stage drug development and clinical studies—have the potential to help reduce R&D costs and accelerate global patient access. Furthermore, there is no doubt of the critical role the global biotech industry plays in ensuring economic recovery and growth. On this panel, experts will share their outlook on this exciting but challenging dynamic and discuss related geopolitical and policy factors at play as well as their implications.